inodiftagene vixteplasmid + gemcitabine

This is a **combination therapy** consisting of inodiftagene vixteplasmid and gemcitabine, both of which are antineoplastic agents used in the treatment of cancer. - **Inodiftagene vixteplasmid (BC-819)** is a recombinant DNA plasmid designed to express diphtheria toxin A (DTA) selectively in malignant cells, under the control of the tumor-specific H19 promoter. This mechanism allows targeted cytotoxicity by inducing cell death only in cancer cells overexpressing the H19 gene, minimizing effects on normal tissue[2][4][5][8]. It is administered via intravesical instillation, mostly for non-muscle invasive bladder cancer (NMIBC)[2][4]. - **Gemcitabine** is a nucleoside analog antimetabolite chemotherapeutic agent that inhibits DNA synthesis, leading to cell death in rapidly dividing cells. It is widely used in the treatment of various solid tumors, including lung, pancreatic, bladder, and breast cancer, typically administered by intravenous injection[1][3][6][7][9]. - The combination is under clinical investigation for enhanced anti-tumor effects in bladder cancer and potentially other malignancies; the goal is to leverage the targeted cytotoxicity of inodiftagene vixteplasmid with the broad cytostatic effects of gemcitabine.

Other names

inodiftagene vixteplasmid + gemcitabine